{"id":16675,"date":"2013-05-30T02:30:00","date_gmt":"2013-05-30T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/ims-health-per-mercato-italiano-1-crescita-annua-al-2017\/"},"modified":"2013-05-30T02:30:00","modified_gmt":"2013-05-30T00:30:00","slug":"ims-health-per-mercato-italiano-1-crescita-annua-al-2017","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/ims-health-per-mercato-italiano-1-crescita-annua-al-2017\/","title":{"rendered":"Ims Health, for the Italian market +1% annual growth to 2017"},"content":{"rendered":"

In the medium term, a moderate growth trend is expected for the Italian pharmaceutical market, a good half of which will take place outside the pharmacy. In fact, in the period 2011-2017 Ims Health estimates a compound annual growth rate (CAGR) equal to 1% and expects that the 50% of the market will materialize, in fact, above all in non-retail channels. From 2009 to 2011 \u2013 as recalled in a report prepared for Pharmakronos \u2013 growth was slowed down by about one percentage point each year and in 2012 this evolution was accentuated leading to a trend of -0.7% on the total market.<\/p>\n

<\/font><\/span><\/p>\n

From now to the next three years, the recovery will be contained. Among the reasons Ims Health indicates the austerity programs and the containment of healthcare costs, implemented as a result of the economic crisis; the intensification of initiatives to increase the use of generic drugs (which currently account for 12.4% of pharmaceutical expenditure) and to limit the reimbursement of medicines, due to the few patents expected to expire; the spread of 'value-based pricing' policies, i.e. fixing the price on the basis of the value of a drug, evaluated according to a series of new methodologies; finally, the growing restrictions also on hospital pharmaceutical expenditure.<\/p>\n

<\/font><\/span><\/p>\n

Barbara Di Chiara \u2013 May 30, 2013 \u2013 PharmaKronos<\/p>\n

<\/span><\/i><\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

  Nel medio termine si prevede per il mercato farmaceutico italiano un trend a crescita contenuta, e che si realizzerà per una buona metà al di fuori della farmacia. Nel periodo 2011-2017 Ims Health stima infatti un tasso di crescita annuale composto (Cagr) pari all’1% e prevede che il 50% del mercato si concretizzerà, appunto, soprattutto …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-16675","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/16675","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=16675"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/16675\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=16675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=16675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=16675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}